Pulse Biosciences Inc
NASDAQ:PLSE
Pulse Biosciences Inc
Pulse Biosciences Inc. operates at the intriguing intersection of healthcare innovation and cutting-edge technology, focusing on the development and commercialization of their proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a novel bio-electrical platform designed to deliver ultra-short electrical pulses designed to induce cell stress and modify cell structure without significantly impacting non-cellular structural elements. The company primarily concentrates on medical applications that demand precision and safety, notably in dermatology, oncology, and other critical therapeutic areas. By developing devices like the CellFX System, Pulse Biosciences allows physicians to treat conditions with minimal invasiveness, offering alternatives to traditional methods like surgery.
Pulse Biosciences generates revenue by selling these medical devices and fostering strategic partnerships within the healthcare sector to expand the application and adoption of NPS technology. The company's business model hinges on convincing healthcare professionals and institutions of the tangible benefits and potential cost savings that their innovative solutions offer. By aligning themselves with clinicians and medical researchers, Pulse Biosciences endeavors to expand the clinical indications for NPS technology, gradually scaling their market presence. Although the journey involves navigating the complex regulatory landscape and proof of clinical efficacy, the company aims to sustain growth through continuous innovation and market expansion, targeting widespread adoption of their groundbreaking platforms.
Pulse Biosciences Inc. operates at the intriguing intersection of healthcare innovation and cutting-edge technology, focusing on the development and commercialization of their proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a novel bio-electrical platform designed to deliver ultra-short electrical pulses designed to induce cell stress and modify cell structure without significantly impacting non-cellular structural elements. The company primarily concentrates on medical applications that demand precision and safety, notably in dermatology, oncology, and other critical therapeutic areas. By developing devices like the CellFX System, Pulse Biosciences allows physicians to treat conditions with minimal invasiveness, offering alternatives to traditional methods like surgery.
Pulse Biosciences generates revenue by selling these medical devices and fostering strategic partnerships within the healthcare sector to expand the application and adoption of NPS technology. The company's business model hinges on convincing healthcare professionals and institutions of the tangible benefits and potential cost savings that their innovative solutions offer. By aligning themselves with clinicians and medical researchers, Pulse Biosciences endeavors to expand the clinical indications for NPS technology, gradually scaling their market presence. Although the journey involves navigating the complex regulatory landscape and proof of clinical efficacy, the company aims to sustain growth through continuous innovation and market expansion, targeting widespread adoption of their groundbreaking platforms.
First Revenues: Pulse Biosciences reported initial revenue of $86,000 in Q3 2025 from limited market release of its nPulse platform and Vybrance disposables.
Clinical Progress: Over 200 patients have now been treated in the Vybrance pilot program, and the PRECISE-BTN study has reached over 40% enrollment.
FDA Milestones: FDA granted IDE approval for the pivotal study of the nPulse surgical ablation clamp for atrial fibrillation, and the first patient has been treated.
Pipeline Advancement: The company expects to begin its IDE clinical study for the nPulse 360 Catheter for AF ablation in Q1 2026.
Growing Expenses: GAAP costs and expenses rose to $20.5 million, primarily due to organizational growth and increased stock-based compensation.
Cash Position: The company ended Q3 with $95.2 million in cash and cash equivalents, with $13 million used in operating activities during the quarter.
Strategic Focus: Management is prioritizing quality therapy development, market access, and carefully managed commercial expansion before scaling sales headcount.
